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Abstract 
There is a concerted research effort to investigate brain mechanisms underlying 
addiction processes that may predicate the development of new compounds for 
treating addiction. One target is the brain’s opioid system, due to its role in the 
reinforcing effects of substances of abuse. Substance-dependent populations have 
increased numbers of the mu opioid receptor (MOR) in fronto-striatal regions that 
predict drug relapse, and demonstrate disturbances in these regions during the 
processing of non-drug rewards. Naltrexone is currently licensed for alcohol and 
opiate dependence, and may remediate such disturbances through the blockade 
of MORs in fronto-striatal reward circuitry. Therefore, we examined the potential 
acute modulating effects of naltrexone on the anticipation of, and instrumental 
responding for, non-drug rewards in long-term abstinent alcoholics, alcoholic poly 
substance-dependent individuals and controls using a monetary incentive delay 
(MID) task during a randomized double blind placebo controlled fMRI study. We 
report that the alcoholic poly substance-dependent group exhibited slower and 
less accurate instrumental responding compared to alcoholics and controls that 
was less evident after acute naltrexone treatment. However, naltrexone treatment 
was unable to remediate disturbances within fronto-striatal regions during reward 
anticipation and “missed” rewards in either substance-dependent group. While we 
have not been able to identify the underlying neural mechanisms for improvement 
observed with naltrexone in the alcoholic poly-substance dependent group, we can 
confirm that both substance-dependent groups exhibit substantial neural deficits 
during an MID task, despite being in long-term abstinence. 
 
 
Introduction 
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 Substance dependence, particularly to alcohol, continues to be a major 
cause of harm to individuals and society (Nutt et al., 2010). Identifying the 
substrates of addiction in an attempt to elucidate potential neural targets for 
future treatment development in substance dependence remains a major 
challenge in neuroscience. One such neural target is the brain’s opioid system, 
given its interactions with the dopamine (DA) system of the brain (Solinas et al., 
2004), and its role in the reinforcing effects of alcohol and other substances of 
abuse (Colasanti et al., 2012; Mick et al., 2014; Spreckelmeyer et al., 2011).  
 
Mu opioid receptor (MOR) numbers are reported to be significantly elevated 
in alcoholic patients in early abstinence (Heinz et al., 2005), particularly in the 
ventral striatum (VS), with increased MOR availability found to correlate with 
alcohol craving (Williams et al., 2009). Similarly, cocaine abusers in early 
abstinence have increased numbers of MORs within fronto-striatal regions 
(Gorelick et al., 2005), which have been found to predict relapse (Gorelick et al., 
2008). A similar pattern has been reported in opiate abstinence (Williams et al., 
2007; Zubieta et al., 2000). There is also good evidence that MOR blockade is 
effective in promoting substance abstinence (Grassi et al., 2007; Krystal et al., 
2001; Srisurapanont et al., 2005). Therefore, disturbances to the brain’s opioid 
system during early abstinence make it a viable target for protection against 
potential alcohol and drug relapse. 
 
Substance abusers, particularly alcoholics, may still be at risk for relapse in 
long-term abstinence due to ongoing and latent disturbances in the brain’s opioid 
system. Opioid disturbances within DA fronto-striatal reward circuitry may confer 
an ongoing risk for relapse to drug rewards if there is a diminished incentive value 
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of, and motivation to procure, non-drug rewards. Naltrexone is currently licensed 
for alcohol dependence, and may remediate these disturbances by restoring some 
balance within key fronto-striatal networks that are critical for optimizing the 
incentive value and attainment of non-drug rewards.  The current study, therefore, 
investigated the effects of acute MOR blockade with naltrexone on fronto-striatal-
dependent reward processing in alcoholics and polysubstance-dependent 
individuals who were in extended abstinence. We hypothesized that 1) alcoholic 
and polysubstance-dependent groups, compared to controls, would demonstrate 
disturbances within fronto-striatal regions in response to the prediction of 
potential non-drug rewards and 2) acute MOR blockade with naltrexone would 
have an ameliorating effect on these neural disturbances, possibly providing a 
credible therapeutic biomarker for treating deficiencies in non-drug reward 
processing that may trigger relapse to addictive behaviour.    
    
Material and Methods 
Participants 
This was a randomized double blind placebo controlled multi-centre study 
involving three study sites in the United Kingdom (Imperial College, Cambridge 
and Manchester - ICCAM). For a more detailed description of the ICCAM Platform, 
see Paterson et al (Paterson et al., 2015).  Inclusion criteria were individuals who 
met DSM-IV criteria for current or prior alcohol dependence (Alcoholminus), or 
alcohol plus (Alcoholplus) another substance of dependence (e.g., amphetamines, 
benzodiazepines, cocaine, opiates) and who would be abstinent for at least 4 
weeks prior to the experimental sessions. There was no upper limit for abstinence 
length. All participants were aged 21 to 64. In the current study, the Alcoholminus 
group was made up of 21 abstinent alcoholics, with the Alcoholplus group comprised 
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of 25 abstinent alcoholic polysubstance-dependent individuals (having met criteria 
for dependence to alcohol plus one or more other substances of dependence). The 
Alcoholplus group was made up of 6 abstinent alcoholics with cocaine dependence; 
6 with cocaine and opiate dependence; 4 with amphetamine, cocaine and opiate 
dependence; 2 with just opiate dependence; 1 with amphetamine, cocaine and 
solvent dependence; 1 with benzodiazepine, cocaine and opiate dependence; 1 
with cocaine and GHB dependence; 1 with benzodiazepine and opiate dependence; 
1 with amphetamine and cocaine dependence; 1 with benzodiazepine and cocaine 
dependence, and 1 with just amphetamine dependence. The healthy control group 
was made up of 35 participants with no previous history of substance abuse, as 
assessed using the ASSIST and timeline follow-back. All participants were required 
to provide a negative breath alcohol test and a negative urine sample for various 
drugs of abuse on both experimental days (screening for the presence of 
amphetamines, benzodiazepines, cannabinoids, cocaine and opiates). 
 
Exclusion criteria included 1) current use of regular prescription or non-
prescription medication that could not be stopped for the study duration, or would 
interfere with study integrity or subject safety (including but not limited to 
antipsychotics, anticonvulsants, antidepressants, disulfiram, acamprosate, 
naltrexone, varenicline);  2) current primary axis I diagnosis, past history of 
psychosis (unless drug-induced); 3) current or past history of enduring severe 
mental illness (e.g., schizophrenia, bipolar affective disorder); 4) other current or 
past psychiatric history that, in the opinion of a psychiatrist, contraindicated 
participation; 5) history or presence of a significant neurological diagnosis that 
may have influenced the outcome or analysis of the results (including but not 
limited to stroke, epilepsy, space occupying lesions, multiple sclerosis, Parkinson's 
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disease, vascular dementia, transient ischemic attack, clinically significant head 
injury);  6) claustrophobia or unable to lie still in the MRI scanner for up to 90 
minutes; 7) presence of a cardiac pacemaker, other electronic device or other MRI 
contraindication, including pregnancy, as assessed by a standard pre-MRI 
questionnaire. Secondary or lifetime history of depression or anxiety was 
permitted in both substance abusers and healthy controls since these are very 
common psychiatric disorders. 
 
Experimental visits 
At the randomised placebo and naltrexone experimental visits, an eligibility 
check was performed. Participants’ intervening drug use and concomitant 
medication were checked and participants completed alcohol breath, pregnancy 
and urine drugs of abuse screening tests. Cigarette smokers in all groups smoked 
ad lib approximately 60 minutes prior to scanning in order to avoid the potential 
confounds of withdrawal and/or craving during scanning.  
 
Medications 
 Drug preparation, labelling and packaging was performed by UCLH 
Pharmacy Manufacturing Unit. Placebo was Vitamin C (100mg, supplier: Sigma, 
manufacturer: Norbrook) and naltrexone (50mg Nalorex® - manufacturer - 
Bristol-Myers Squibb) were prepared and packaged according to Investigational 
Medicinal Product guidelines. The maximum naltrexone plasma concentration after 
an acute 50 mg dose is 0.5-3 hours (Meyer et al., 1984). Therefore, participants 
were dosed two hours prior to each experimental scan session to ensure high MOR 
occupancy during testing. Naltrexone and placebo medications were supplied in 
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identical white opaque bottles and administered by independent nursing staff, 
such that both researcher and participant remained blinded. 
 
Monetary Incentive Delay Task (MID) 
We used a “monetary incentive delay task” (MID), which was based on that 
originally employed by Knutson (Knutson et al., 2001). While being scanned on 
the placebo and naltrexone experimental sessions, participants performed the MID 
task, during which they anticipated potential monetary gain, loss or no potential 
monetary outcome. During each trial, participants viewed one of three symbols (a 
cue) that indicated the potential to win fifty pence (square containing an ascending 
arrow), lose fifty pence (square containing a descending arrow) or experience no 
financial outcome (square containing a horizontal line - here referred to as a 
neutral trial). Each cue was presented for one second, with a variable duration (2-
4 sec) for the subsequent anticipation period. Following the anticipation period, 
participants made a button press response upon the presentation of a visual target 
(star located within a circle). Following their response to the visual target, 
participants received feedback (1500 ms) as to whether they were successful or 
unsuccessful (“Hit” or “Miss” respectively) on each trial, and also saw a running 
total of their winnings up to that point in the task. Following the feedback, there 
was an end fixation period (3-5 sec) before the commencement of the next trial.  
 
 
Because the primary objective of this study was to examine the neural 
correlates of reward processing, we chose to use a smaller number of loss trials 
in an attempt to increase the incentive salience of win trials during the task. 
Consequently, there were a total of 18 “win”, 6 “lose” and 18 “neutral” trials on 
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each run of the task. The MID task was additionally tailored to adapt to the visual 
target reaction time of each participant by using a staircase algorithm, such that 
the presentation of the visual target became shorter as performance improved 
during the experiment. This staircase algorithm enabled us to set a limit on the 
success rate of each participant (~66%), which additionally served to incentivize 
participants to engage in the task. Participants were instructed to maximize their 
winnings and were told they would receive them at the end of the study. 
Dependent measures were percentage accuracy and mean reaction time 
(milliseconds) to the visual target on each of the MID trials. There were two 
functional MRI runs of the task (432 seconds each). The task was programmed 
using E-Prime version 2.0 (Psychology Software Tools, Pittsburgh, USA).  
 
Functional MRI (fMRI) Data Acquisition  
 All centres operated MRI machines with a main magnetic field of 3 tesla (T). 
Centres in London and Cambridge operated nominally identical 3T Siemens Tim 
Trio systems running the syngo MR B17 software with a Siemens 32 channel 
receive-only phased-array head coil. The Manchester centre operated a 3T Philips 
Achieva running version 2.6.3.5 software and an 8 element SENSE head coil. For 
anatomical images, 160 high-resolution T1-weighted anatomic MPRAGE axial 
images (FOV 256 mm, thickness 1.0 mm, voxel size 1.0×1.0×1.0) were acquired 
(total duration 303 s). Functional data were acquired using a T2* weighted echo-
planar imaging sequence collecting 36 non-contiguous (0% gap) 3.0 mm axial 
slices covering the entire brain (TE=31 ms, TR=2000 ms, FOV 225 mm, 64×64 
mm matrix size in Fourier space). The two runs of the MID task produced a total 
of 432 volumes of functional MRI data. 
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MID fMRI data analyses 
Data pre-processing and statistical analysis were conducted using FEAT 
(fMRI Expert Analysis Tool) from the FMRIB Software Library 
(www.fmrib.ox.ac.uk/fsl). Pre-statistical processing was as follows: motion 
correction utilizing FMRIB’s Linear Image Registration Tool (MCFLIRT; non-brain 
matter removal using Brain Extraction Tool (BET); spatial smoothing with a 5-mm 
full-width half maximum Gaussian kernel; mean-based intensity normalization; 
nonlinear high-pass temporal filtering (Gaussian-weighted least squares straight 
line fit, with sigma = 25.0 sec). The six rigid body movement parameters were also 
included as regressors in the model in FSL FEAT.  
For each participant, first level whole-brain mixed-effects analyses were 
performed by modelling the MID anticipation periods (i.e. Neutral, Win) as 
explanatory variables within the context of the general linear model on a voxel-
by-voxel basis (variable boxcar functions for the cue + variable anticipation period 
regressors were convolved with the haemodynamic response function). The win 
and neutral outcome periods (“Hit” and “Miss”) were also modelled (stick functions 
for “hit” and “miss” trial period regressors were convolved with the haemodynamic 
response function). During these first level analyses, the win anticipation>neutral 
anticipation, win hit>neutral hit and win miss>neutral miss contrasts was 
formulated. Owing to the small number of loss trials in the current task, the loss 
cue + anticipation and outcome periods were regressed out of the functional time 
series as conditions of no interest. The end fixation period of the task served as 
the implicit baseline. Registration was conducted through a two-step procedure, 
whereby EPI images were first registered to the high-resolution T1 structural 
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image, then into standard (Montreal Neurological Institute, MNI avg152 template) 
space, with 12-parameter affine transformations.  
Two (Group: alcoholminus & alcoholplus combined vs. control) by two (Drug: 
placebo vs. naltrexone) whole brain cluster-based repeated measures ANOVA 
analyses were performed as part of a higher-level mixed-effects analysis on the 
win anticipation>neutral anticipation, win hit>neutral hit and win miss>neutral 
miss contrasts. These higher-level analyses were conducted using FLAME (FMRIB's 
Local Analysis of Mixed Effects). Cluster (Gaussianised F) statistical images were 
determined by Z>2.3 with a corrected cluster significance threshold of p<0.05. 
This ANOVA analysis produced a total of three (i.e. drug effect, group effect, drug 
x group interaction) zF statistical images.  
 
Other Statistics 
 Between groups demographics (see Table 1.) were examined using 
Kruskal–Wallis (gender distribution and drug order) or one-way ANOVA analyses. 
For analyses conducted on the MID behavioural data, we used a three (Group: 
alcoholminus vs. alcoholplus vs. control) by two (Drug: placebo vs. naltrexone) by 
two (Condition: neutral vs. win) repeated measures ANOVA analyses. We also 
conducted a three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: 
placebo vs. naltrexone) repeated measures ANOVA on an index of the relative 
motivational value (RMV). This value is based on the ratio of mean reaction times 
to the target on neutral trials compared to that on win trials - i.e. RT neutral/RT win. 
Here a value >1 reflects a higher relative value of monetary incentives (Sescousse 
et al., 2015), and which more closely reflects the contrasts in the incentive value 
of these conditions computed during the functional MRI analyses. We extracted 
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the mean BOLD signal change from the group zF-statistic ANOVA clusters and 
conducted three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: 
placebo vs. naltrexone) repeated measures ANOVA analyses to explore the 
direction of the effects observed in the cluster-based analyses. All analyses were 
conducted using the Statistical Package for the Social Sciences (SPSS Inc., 
Chicago). 
 
Results 
Demographics 
Table 1 shows the between group demographics for the control, alcoholminus 
and alcoholplus groups. The groups significantly differed on most of the measures 
reported herein, including age (alcoholminus>alcoholplus & control), years of 
education (alcoholplus<control), IQ (alcoholplus<control), alcohol exposure (control 
& alcoholplus<alcoholminus), and cigarette (alcoholplus>control) and cannabis 
(alcoholplus>alcoholminus & control) use history. The groups did not differ on 
handedness score or gender distribution. We further report that the groups did 
not differ significantly on drug treatment order (χ2 = 0.48, df=2, p> 0.7) during 
the study.  
 
-Insert Table 1 about here- 
 
MID Performance 
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 Figure 1A below shows the mean MID accuracy (%) for the two conditions 
in the alcoholminus, alcoholplus and control groups during the placebo and naltrexone 
sessions. A three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: 
placebo vs. naltrexone) by two (Condition: neutral vs. win) repeated measures 
ANOVA showed a significant effect of condition (F=46.3; df=1, 78; p<0.001 - 
win>neutral) and a significant drug x group interaction (F=4.04; df=2, 78; 
p<0.05). Follow-up analyses revealed that, across MID conditions, the alcoholplus 
group was significantly less accurate than both the alcoholminus (p<0.001) and 
control (p<0.01) groups during the placebo session only. Figure 1B below shows 
the mean MID reaction time (milliseconds) for the two conditions. The same 
ANOVA demonstrated a significant effect of condition (F=63.6; df=1, 78; p<0.001 
- win<neutral) and a significant drug x group interaction (F=4.07; df=2, 78; 
p<0.05). Follow-up analyses revealed that, across MID conditions, the alcoholplus 
group was significantly slower than both the alcoholminus and controls groups 
(p<0.05) during the placebo session only. Finally, figure 1C shows the computed 
index of the RMV. A three (Group: alcoholminus vs. alcoholplus vs. control) by two 
(Drug: placebo vs. naltrexone) repeated measures ANOVA showed no effect of 
drug (F=0.61; df=1, 78; p=0.43), group (F=0.45; df=2, 78; p=0.63) or a drug x 
group interaction (F=0.62; df=2, 78; p=0.53) on this index, however.   
 
-Insert Figure 1 about here- 
 
 
Functional MRI 
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 All three groups demonstrated statistically significant activation patterns 
across fronto-striatal regions during the placebo and naltrexone challenges for the 
win anticipation>neutral anticipation contrast at a whole brain level (see 
Supplementary Figs 1 & 2). As we did not observe any significant group x drug 
interactions for a three (Group: alcoholminus vs. alcoholplus vs. control) by two 
(Drug: placebo vs. naltrexone) whole brain cluster-based repeated measures 
ANOVA, we decided to collapse across the two substance groups in order to 
increase the power to detect clusters related to a main effect of group. The two 
(Group: alcoholminus & alcoholplus combined vs. control) by two (Drug: placebo vs. 
naltrexone) whole brain cluster-based repeated measures ANOVA analyses 
showed a significant main effect for group (see Supplementary Fig 3), but did not 
reveal a significant main effect for drug or a drug x group interaction. Table 2 
shows the cluster-based statistics from this ANOVA group effect, which comprised 
12 separate clusters covering cerebellar, occipital, temporal, frontal and striatal 
regions. 
 
-Insert Table 2 about here- 
 
In order to assess the direction of the observed group effect, we performed three 
(Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: placebo vs. 
naltrexone) repeated measures ANOVA analyses on the mean BOLD signal change 
within each of the group ANOVA zF-statistic clusters. These were performed in 
order to reveal whether the alcoholminus and alcoholplus groups independently 
contributed to the main ANOVA group effect.  
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In the left orbitofrontal cortex (OFC) cluster, there was a main effect of 
group (F=5.25; df=2, 78; p<0.01), which revealed that only the alcoholplus group 
was significantly lower than the control group (p<0.01- Fig 2A) in this region. 
Within the right inferior frontal gyrus (IFG)/insula cluster, however, a main effect 
of group (F=4.25; df=2, 78; p<0.05) showed that there was a significant BOLD 
signal reduction in both the alcoholminus and alcoholplus groups (p<0.05 - Fig 2B) 
compared to the control group. There was also a main effect of group in the left 
(F=4.17; df=2, 78; p<0.05) and right (F=4.12; df=2, 78; p<0.05) ventral 
caudate/nucleus accumbens (NAcc) showing that the alcoholminus group (p<0.05), 
and to a greater degree, the alcoholplus group (p<0.01) exhibited a significantly 
lower BOLD signal change than the control group across these striatal regions (Fig 
3A & 3B).  
-Insert Figure 2 about here- 
-Insert Figure 3 about here- 
Additionally, there was a significant effect of group in the right frontal pole 
cluster (F=6.23; df=2, 78; p<0.05 - alcoholminus<control, p<0.05; 
alcoholplus<control, p<0.01); right cerebellum cluster (F=3.5; df=2, 78; p<0.05 - 
alcoholplus<control, p<0.05); right parahippocampal gyrus cluster (F=6.40; df=2, 
78; p<0.01 - alcoholminus<control, p<0.05; alcoholplus<control, p<0.01); right 
supramarginal gyrus cluster (F=4.10; df=2, 78; p<0.05 - alcoholminus and 
alcoholplus<control, p<0.05); left middle temporal gyrus/parahippocampal gyrus 
cluster (F=7.73; df=2, 78; p<0.01 - alcoholminus<control, p<0.05; 
alcoholplus<control, p<0.001) and the left occipital fusiform gyrus cluster (F=3.32; 
df=2, 78; p<0.05 - alcoholplus<control, p<0.05). We did not, however, observe a 
significant effect of group in either the left (F=2.21; df=2, 78; p<0.1) or right 
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(F=2.25; df=2, 78; p<0.09) anterior cingulate cortex (ACC) clusters, suggesting 
that the original observed group effect in this region was due to a conflation of the 
alcoholminus and alcoholplus groups. In order to confirm this, we collapsed across the 
two groups and conducted a Two (Group: alcoholminus & alcoholplus combined vs. 
control) by two (Drug: placebo vs. naltrexone) repeated measures ANOVA to 
verify a significant effect of group in the left (F=4.88; df=1, 79; p<0.5 - 
alcoholminus & alcoholplus combined<control - Fig 4A), and right (F=5.06; df=1, 79; 
p<0.5 - alcoholminus & alcoholplus combined<control - Fig 4B) ACC clusters. 
-Insert Figure 4 about here- 
The same whole brain cluster-based repeated measures ANOVA analysis 
also revealed a significant main effect of group for the win miss>neutral miss 
contrast in the left insula (140 voxels; x=-42; y=14; z=-12; zF=3.72; df=1, 79; 
p<0.001) and the right ACC (415 voxels; x=4; y=44; z=4; zF=3.51; df=1, 79; 
p<0.001) only. As with the anticipation contrast, we additionally conducted the 
same three by two repeated measures ANOVA on the mean BOLD signal change 
within these two clusters. There was a significant effect of group in the left insula 
(F=4.51; df=2, 78; p<0.05 - alcoholminus and alcoholplus<control, p<0.05 - Fig 5A) 
and in the right ACC (F=4.21; df=2, 78; p<0.05 - alcoholminus and 
alcoholplus<control, p<0.05 - Fig 5B), showing that the alcoholminus and alcoholplus 
groups independently contributed main ANOVA group effect. This same analysis 
also showed a trend towards a drug effect in both the insula (F=2.87; df=1, 78; 
p=0.09) and ACC (F=3.13; df=1, 78; p=0.08) clusters, likely driven by the 
direction of signal change on the naltrexone session in the alcoholminus and 
alcoholplus groups. Therefore, we additionally performed post hoc within group 
paired t-test analyses and showed that in the alcoholplus group only, there was a 
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attenuation of the BOLD signal change during the naltrexone compared to the 
placebo session in both the insula (-t=2.12; df=24, p<0.05) and the ACC (-
t=2.26; df=24, p<0.05) clusters. There were no significant main effects for the 
win hit>neutral hit contrast. 
-Insert Figure 5 about here- 
Discussion 
This study set out to examine fronto-striatal activation during reward 
anticipation and instrumental responding in long-term abstinent alcoholic and 
alcoholic polysubstance-dependent individuals in order to evaluate the acute 
modulating effects of MOR blockade on these processes. The study showed that 
the alcoholplus group exhibited slower and less accurate instrumental responding 
across MID conditions compared to both the alcoholminus and control groups during 
the placebo session, an effect that was less evident after naltrexone but with no 
absolute improvement in speed and accuracy of responding as a result of drug 
treatment. The study additionally showed, however, that while there were no 
effects on the relative motivational value (RMV) for rewards, there were 
disturbances within fronto-striatal regions during reward anticipation and “missed” 
rewards in both substance dependent groups that were not reliably remediated by 
acute naltrexone treatment.  
The observed slower and less accurate responding of the alcoholplus group 
may suggest a low degree of motivation during the sustained cognitive demands 
of general instrumental effort. Using a behavioural motivational index that 
specifically reflects a higher relative value for reward incentives during 
instrumental responding, however, we observed no difference between groups or 
any effects of naltrexone. The apparent remediation produced by acute naltrexone 
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in the alcoholplus group seems most likely to be a consequence of changes in 
response to naltrexone in the comparison groups as there was little evidence of 
absolute improvements in behavioural functioning produced by naltrexone in the 
alcoholplus group. 
 
Reduced BOLD activation changes in the alcoholplus group 
Under conditions of reward anticipation, the alcoholplus group exhibited 
significantly lower activation change in the OFC compared with that of the control 
group across drug treatments. There is previous evidence of hypofunctioning in 
the OFC (London et al., 2000), particularly during abstinence (Volkow et al., 
1992). The OFC  has important functional connections with the striatum (Volkow 
et al., 2000), and is known to code the motivational value of stimuli (Koeneke et 
al., 2008). The OFC also contains a high number of MOR (Gorelick et al., 2005), 
suggesting that any disturbance to the brain’s opioid system might be modulated 
by naltrexone. The current results, however, provide no evidence for an acute 
modulatory effect in the OFC, instead suggesting that disturbances within striato-
orbitofrontal circuitry that subserves reward prediction and motivational 
processes, are sustained in long-term polysubstance, but not alcohol, abstinence.  
 
 
 
Independent BOLD activation reductions in the alcoholminus and alcoholplus groups 
Compared to controls, the alcoholminus, and to a greater degree, the 
alcoholplus group, exhibited reduced bilateral ventral caudate/NAcc activation in 
response to the anticipation of potential monetary rewards. The current result 
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concurs with previous research findings of altered striatal activity for non-drug 
rewards in substance dependence (Buhler et al., 2010; Bustamante et al., 2014; 
Diekhof et al., 2008; Gradin et al., 2014; Peters et al., 2011; Wrase et al., 2007) 
and may be consistent with a sustained striatal reward deficiency syndrome (Blum 
et al., 2000; Koob et al., 2004) in long-term substance abstinence. There are also 
high levels of MORs in the caudate (Arvidsson et al., 1995), making this region a 
credible target for modulation with naltrexone. The current findings, however, do 
not appear to support a remediating effect of naltrexone in this particular 
behavioural context. 
The current study also found that both the alcoholminus and alcoholplus groups 
demonstrated reduced activation changes compared with controls in the frontal 
pole and IFG/insula regions during reward anticipation. The PFC represents both 
cognitive and reward-related information processing (Watanabe et al., 2007), 
whereas the insula is implicated in reward and risk prediction (Preuschoff et al., 
2008) and addiction relapse (Paulus et al., 2005; Seo et al., 2013), possibly due 
to its role in awareness of interoceptive (i.e. bodily) states (Critchley et al., 2004). 
The current findings may, therefore, suggest that in long-term alcohol and 
polysubstance abstinence, there are sustained disturbances within a network of 
regions that function to integrate the cognitive interpretation of motivational 
drives (Goldstein et al., 2007) and other emotional and interoceptive states.   
 
We also observed that the alcoholminus and alcoholplus groups exhibited 
reduced activation changes compared with controls in the anterior insula, and 
notably, the rostral ACC (rACC) during “missed” rewards. The rACC has been 
labelled as the “affective division” of the cingulate (Bush et al., 2000; Devinsky et 
al., 1995), through processing the emotional components of errors (Luu et al., 
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2003; van Veen et al., 2002). The observed decrease in error-related rACC and 
insula activation may have resulted from decreases in arousal during misses, an 
effect that was apparently exacerbated by acute opioid blockade with naltrexone. 
This blunting of error-related signalling by naltrexone in substance abusers may 
have clinical implications, where arousal and conflict monitoring are necessary 
responses to violations in prediction that require adjustments to ongoing 
behaviour during treatment.  The effects of naltrexone in the insula and ACC, 
however, may encourage further investigations regarding the effects of opioid 
blockade on error-related neural responses in addiction populations. 
        
Interdependent BOLD activation reductions in the alcoholminus and alcoholplus groups 
 
When combined, the alcoholminus and alcoholplus groups exhibited reduced 
activations in the ACC during the anticipation of monetary reward compared to 
controls that were not modulated by naltrexone. The ACC has been implicated in 
addiction and its cognitive sequelae (Goldstein et al., 2002; Peoples, 2002; Volkow 
et al., 2002), with disturbances in this region reported in a number of abstinent 
substance abusing populations (Bolla et al., 2004; Eldreth et al., 2004; Nestor et 
al., 2011; Salloum et al., 2007). One of these differences was observed for the 
caudal dorsal ACC (cdACC), a region involved in processing the value of actions, 
motivation and expected outcomes under conditions of reward (Kouneiher et al., 
2009). This may suggest that neural processing within a motivational and reward 
prediction cognitive network remains compromised in long-term substance 
abstinence.  
 
Limitations of the current study include a lack of complete matching of 
groups with respect to age, cannabis and cigarette use, anxiety and mood 
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measures, which means we cannot unequivocally dismiss their potential influence 
on altered reward processing in fronto-striatal circuitry of both the alcoholminus and 
alcoholplus groups. Furthermore, we did not thoroughly assess alcohol and drug 
craving at each session across the groups, which may have had a possible 
influence on our metrics of motivation and reward processing. Moreover, 
dependence on (and abstinent from) multiple and varying substances of abuse in 
the alcoholplus group underpowered us to statistically examine the influence of 
these measures on indices of motivation and reward processing. While our groups 
were well matched on the distribution of gender, the small number of females in 
each group did not permit us to examine the influence of gender effects on the 
neurobiology of reward and motivational processes in the two substance-
dependent groups.  The reduced number of loss trials in our MID task also meant 
we were unable to examine the neural correlates of loss anticipation and outcome, 
where sensitivity to punishment may well have implications for treatment and 
drug relapse. 
 
In summary, the current study set out to map the impact of MOR blockade 
upon neural networks disrupted in substance dependence and has demonstrated 
evidence of sustained disturbances within fronto-striatal regions of long-term 
abstinent alcoholics and polysubstance-dependent individuals. It has also shown 
that acute naltrexone treatment produced a relative minor amelioration of 
behavioural performance on a monetary delayed incentive task in an alcoholic, 
polydrug abuser group (alcoholplus), but not in a group of patients with “pure” 
alcoholic abuse (alcoholminus). Moreover, naltrexone was unable to reverse neural 
changes in fronto-striatal systems associated with the MID task, possibly 
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suggesting the potential insensitivity of this task for elucidating possible 
therapeutic effects on neural biomarkers in future experimental medicine studies.  
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Table 1. Demographic variables for the control, alcoholminus and alcoholplus groups. Age *p<0.05 - alcoholminus>alcoholplus & 
control; Edu **p<0.01 - alcoholplus<control; IQ *p<0.05 - alcoholplus<control; Alcohol Exposure ***p<0.001 
control<alcoholminus & *p<0.05 - alcoholplus<alcoholminus; Cigarette Use **p<0.01 - alcoholplus>control; Cannabis Use 
***p<0.001 - alcoholplus>alcoholminus & control. Also shown are the months of abstinence from alcohol in all three groups and 
additional substances of dependence in the alcoholplus group. Data are expressed as means ± SEM. Ranges of substance 
asbtinence are also provided in parentheses.  
 
    
   Control (n=35) AlcoholMinus (n=21) AlcoholPlus (n=25) 
Gender (Female/Male)     7/28      4/17  6/19 
Age   41.11 ± 1.54     46.23 ± 1.96*                    39.60 ± 1.52 
Edu   13.45 ± 0.45   12.66 ± 0.65    11.32 ± 0.42** 
IQ 105.91 ± 1.71 105.28 ± 1.82  99.36 ± 2.39* 
Handedness   46.08 ± 9.75     55.74 ± 14.12  62.91 ± 11.22 
Alcohol Exposure (yrs)          0.80 ± 0.44***   18.71 ± 1.88  13.42 ± 1.94* 
Cigarette Use (pack yrs)     9.99 ± 2.11   17.44 ± 4.45    22.27 ± 3.31** 
Cannabis Use (yrs)     0.34 ± 0.34     2.80 ± 1.05       8.64 ± 1.78*** 
Alcohol Abstinence (mths)           0.34 ± 0.2 (5.0)             14.08 ± 4.23 (78.5)          13.69 ± 2.50 (34.5) 
Cocaine Abstinence (mths)    -     -          24.10 ± 4.86 (82.5) 
Opiate Abstinence (mths)    -     -           39.47 ± 14.75 (274) 
Amphetamine Abstinence (mths)    -     -         156.85 ± 51.48 (306) 
Benzodiazepine Abstinence (mths)    -     -              64.50 ± 51.87 (161.5) 
GHB Abstinence (mths)    -     -        36.0 ± 0.00 (0) 
Solvent Abstinence (mths)    -     -      396.0 ± 0.00 (0) 
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Table 2. ANOVA group effect clusters from a two (Group: alcoholminus & alcoholplus combined vs. control) by two (Drug: placebo 
vs. naltrexone) whole-brain cluster-based repeated measures ANOVA for the win anticipation>neutral anticipation contrast. 
Statistical images were first thresholded using clusters determined by Z>2.3 with a corrected cluster significance level of 
p<0.05. The P value corresponding to the maximum zF-statistic within each cluster is shown. Co-ordinates are represented in 
Montreal Neurological Institute (MNI) space.  
        
 
      Voxel 
Cluster Region Voxels p value HS x(mm) y(mm) z(mm) zF-Stat 
 
       
Occipital Fusiform Gyrus 798 <0.0001 L -46 -66 -20 6.41 
Inferior Frontal Gyrus/Insula 351 <0.0001 R 52 16 -2 4.56 
Middle Temporal/Parahippocampal Gyrus 324 <0.0001 L -60 -14 -16 3.72 
Supramarginal Gyrus 319 <0.0001 R 68 -34 36 3.47 
Parahippocampal Gyrus 228 <0.001 R 36 -28 -14 4.37 
Caudate/Nucleus Accumbens 214 <0.01 L -8 14 -2 3.65 
Cerebellum 194 <0.01 R 22 -46 -24 3.36 
Anterior Cingulate Cortex 192 <0.01 L -1 -8 32 4.08 
Anterior Cingulate Cortex 182 <0.01 R 6 18 28 4.22 
Caudate/Nucleus Accumbens 162 <0.01 R 10 10 4 3.45 
Frontal Pole 155 <0.05 R 20 58 -8 4.10 
Orbitofrontal Cortex 147 <0.05 L -30 32 -14 5.04 
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Figure 1. MID task performance in the alcoholminus, alcoholplus and control groups 
during the placebo and naltrexone sessions for A) mean percentage accuracy; B) 
mean reaction time and C) relative motivational value (RMV). Accuracy and 
reaction time data were analyzed using a three (Group: alcoholminus vs. alcoholplus 
vs. control) by two (Drug: placebo vs. naltrexone) by two (Condition: neutral vs. 
win) repeated measures ANOVA. RMV was analysed using a three (Group: 
alcoholminus vs. alcoholplus vs. control) by two (Drug: placebo vs. naltrexone) 
repeated measures ANOVA. MID accuracy: p<0.001 - Win>Neutral; **p<0.01 - 
alcoholplus<control on placebo; ***p<0.001 - alcoholplus<alcoholminus on placebo. 
MID reaction time: p<0.001 - Win<Neutral; *p<0.05 - alcoholplus<alcoholminus & 
control on placebo. Data are expressed as means ± SEM. 
 
Figure 2. Three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: 
placebo vs. naltrexone) repeated measures ANOVA on the mean BOLD signal 
change scores within the group ANOVA zF-statistic clusters for the win 
anticipation>neutral anticipation contrast. Results showed that the alcoholplus 
group had significantly less activation change in A) the left OFC compared to the 
control group (**p<0.01) and that the control group had significantly greater 
activation change in B) the right IFG/insula compared to both the alcoholminus and 
alcoholplus  groups (*p<0.05). Data are expressed as means ± SEM. Co-ordinates 
are represented in Montreal Neurological Institute (MNI) space. OFC: orbitofrontal 
cortex; IFG: inferior frontal gyrus. 
 
Figure 3. Three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: 
placebo vs. naltrexone) repeated measures ANOVA on the mean BOLD signal 
change scores within the group ANOVA zF-statistic clusters for the win 
anticipation>neutral anticipation contrast. Results showed that the control group 
had significantly greater activation change in A) the right caudate/NAcc compared 
to both the alcoholminus (*p<0.05) and alcoholplus (**p<0.01) groups and in B) the 
left caudate/NAcc compared to both the alcoholminus (*p<0.05) and alcoholplus 
(**p<0.01) groups. Data are expressed as means ± SEM. Co-ordinates are 
represented in Montreal Neurological Institute (MNI) space. NAcc: nucleus 
accumbens. 
 
Figure 4. Two (Group: alcoholminus & alcoholplus combined vs. control) by two 
(Drug: placebo vs. naltrexone) repeated measures ANOVA on the mean BOLD 
signal change scores within the group ANOVA zF-statistic clusters for the win 
anticipation>neutral anticipation contrast. Results showed that the control group 
had significantly greater activation change in A) the left anterior cingulate cortex 
(*p<0.05) and in B) the right anterior cingulate cortex (*p<0.05) compared to 
alcoholminus & alcoholplus combined. Data are expressed as means ± SEM. Co-
ordinates are represented in Montreal Neurological Institute (MNI) space. 
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Figure 5. Three (Group: alcoholminus vs. alcoholplus vs. control) by two (Drug: 
placebo vs. naltrexone) repeated measures ANOVA on the mean BOLD signal 
change scores within the two group ANOVA zF-statistic clusters for the win 
miss>neutral miss contrast. Results showed that the control group had 
significantly greater activation change in A) the left insula (*p<0.05) and in B) the 
right anterior cingulate cortex (*p<0.05) compared to both the alcoholminus and 
alcoholplus groups. Within group analyses also revealed that the alcoholplus group 
had a greater BOLD signal reduction on naltrexone compared to placebo in both 
these regions (p<0.05). Data are expressed as means ± SEM. Co-ordinates are 
represented in Montreal Neurological Institute (MNI) space. 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Supplementary Figure 1. Showing average BOLD activation changes across the 
whole brain for the win anticipation > neutral anticipation contrast during the 
placebo session in the alcoholminus, alcoholplus and control groups. Z (Gaussianized 
T) statistic images were thresholded using clusters determined by Z>2.3 and 
corrected cluster significance level of p<0.05. The scale represents the colour 
(from dark to light yellow) of the cluster corresponding to the increasing Z-
statistic. The structural image represents the MNI152 average normal brain with 
corresponding horizontal coordinates (inferior-superior). 
Supplementary Figure 2. Showing average BOLD activation across the whole 
brain for the win anticipation > neutral anticipation contrast during the naltrexone 
session in the alcoholminus, alcoholplus and control groups. Z (Gaussianized T) 
statistic images were thresholded using clusters determined by Z>2.3 and 
corrected cluster significance level of p<0.05. The scale represents the colour 
(from dark to light yellow) of the cluster corresponding to the increasing Z-
statistic. The structural image represents the MNI152 average normal brain with 
corresponding horizontal coordinates (inferior-superior). 
Supplementary Figure 3. ANOVA group effect zF-Statistical map from a two 
(Group: alcoholminus & alcoholplus combined vs. control) by two (Drug: placebo vs. 
naltrexone) whole-brain cluster-based repeated measures ANOVA for the win 
anticipation>neutral anticipation contrast. Statistical images were first 
thresholded using clusters determined by Z>2.3 with a corrected cluster 
significance level of p<0.05. The scale represents the colour (from dark to light 
yellow) of the cluster voxels corresponding to the increasing zF-statistic. Co-
ordinates are represented in Montreal Neurological Institute (MNI) space. 
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Supplementary Figure 1. 
 
Supplementary Figure 2. 
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Supplementary Figure 3. 
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